Magnetic resonance (MR) imaging as a marker for multiple sclerosis

Biomedicine and Pharmacotherapy

Volumn 53, Issue 8, 1999, Pages 351-357

  Castelijns, J A ^a   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CYCLOSPORIN DERIVATIVE; GADOLINIUM PENTETATE; GLATIRAMER; INTERFERON BETA SERINE; METHISOPRINOL; MITOXANTRONE; OKT 4; RECOMBINANT ALPHA INTERFERON; ROQUINIMEX; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW;

EID: 0033197693     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80106-1     Document Type: Article

References (44)

1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983 ; 43 : 662-7.
2. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiatry 1991 : 54 : 683-8.
3. Kurtke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983 ; 33 : 1444-52.
4. Noseworthy JH. Clinical scoring methods tor multiple sclerosis. Ann Neurol 1994 ; 36 : S80-5.
5. Miller DH, Barkhof F, Mnauta JJP. Gadolineum enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993 ; 116 : 1077-94.
6. Miller DH, Barkhof F, Albert PS, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques to monitor the treatment of multiple sclerosis. Ann Neurol 1996 ; 39 : 6-16.
7. Barkhof F, Filippi M, van Waesberghe JHTM, Molyneux P, Rovaris M, Lycklama a Nijeholt GJ, et al. Improving inter-observer variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997 ; 49 : 1682-8.
8. Uhlenbrock D, Sehlen S. The value of T1-weighted images in the differentiation between MS, white matter lesions, and Subcortical Arteriosclerotic Encephalopathy (SAE). Neuroradiology 1989 ; 31 : 203-12.
9. van Walderveen MAA, Kamphorst W, Scheltens P, van Waesberghe JHTM, Ravid R, Valk J, et al. Histophatologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998 ; 50 : 1282-8.
10. van Waesberghe JHTM, van Walderveen MAA, Castelijns JA, Scheltens P, Lycklama a Nijeholt GJ, Polman Ch, et al. Patterns of lesions development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998 ; 19(4) : 675-83.
11. van Waesberghe JHTM, Castelijns JA, Lazeron RH, Lycklama a Nijeholt GJ, Barkhof F. Magnetization Transfer Contrast (MTC) and long repetition time spin-echo MR imaging in multiple sclerosis. Magn Reson Imaging 1998 ; 16 : 351-8.
12. Koopmans RA, Li DK, Oger JJ, Kastrukoff LF, Jardine C, Costley L, et al. Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months. Ann Neurol 1989 ; 26 : 248-56.
13. Isaac C, Li DK, Genton M, Jardine C, Grochowski E, Palmer E, et al. Multiple sclerosis: A serial study using MRI in relapsing patients. Neurology 1988 ; 38 : 1511-5.
14. The IFBN Multiple Sclerosis study group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995 ; 45 : 1277-85.
15. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1998 ; 122 : 3-24.
16. Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology 1995 ; 45 : 255-60.
17. Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG. Moseley IF, et al. Serial gadolineum enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988 ; 111 : 927-39.
18. Thompson AJ, Miller D, Youl B, MacManus D, Moore S. Kingsley D, et al. Serial gadolineum-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992 ; 42 : 60-3.
19. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzales-Scarano F. Multiple sclerosis: Serial study of gadolineum-enhanced MR imaging. Radiology 1988 ; 169 : 117-22.
20. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trials. Ann Neurol 1994 ; 36 : S86-90.
21. Khoury SJ, Guttmann CR, Orav EJ, Hohol MJ, Ahn SS, Hsu L. et al. Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden. Neurology 1994 ; 44 : 2120-4.
22. McDonald WI, Miller DH, Thompson AJ. Are magnetic resonance findings predicitve of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon beta. Ann Neurol 1994 ; 36 : 14-8.
23. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolineum-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Brain 1993 ; 116 : 1077-94.
24. van Waesberghe JHTM, Castelijns JA, Roser W, Silver N, Yousry T, Lycklama a Nijeholt GJ, et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. Am J Neuroradiol 1997 ; 18 : 1279-85.
25. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994 ; 36 : S91-4.
26. Lui C, Li Wan Po A, Mlumhardt LD. 'Summary measure' statistic for assessing the outcome of treatment trials in relapse-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998 ; 64 : 726-9.
27. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995 ; 37 : 661-9.
28. Carlo P, Koudriavtseva T, Gasperini C, Bastianello S, Butinelli C, Faroni J, et al. The effect of IFNβ-1a on monthly gadolinium-enhanced MRI and relapse rate in multiple sclerosis: Results of nine month treatment period. Neurology 1996 ; 46 : A406.
29. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994 ; 44 : 406-13.
30. Bastianello S, Pozzili C, D'Andrea F, Millefiorini E, Trojano M, Morino S, et al. A controlled trial of mitoxantrone in multiple sclerosis; serial MRI evaluation at one year. Can J Neurol Sci 1994 ; 21 : 266-70.
31. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995 ; 37 : 113-9.
32. Edan G. Demonstration of efficacy of mitoxantrone (MTX) using MRI in MS patients with very active disease. J Neuroimmunol 1995 ; Suppl 1 : 16.
33. Moreau T, Thorpe J, Miller DH, Moseley I, Hale G, Waldmann H, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994 ; 344 : 298-301.
34. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladrabine in treatment of chronic progressive multiple sclerosis. Lancet 1994 ; 344 : 9-13.
35. Karussis D, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, et al. Treatment of secondary progressive multiple sclerosis with the immuno-modulator linomide: Results of a double-blind placebo-controlled study with monthly MRI evaluation. Neurology 1995 ; 45 Suppl 4 : 417.
36. Barkhof F, Thompson AJ, Hodgkinson S, van Oosten B, Lai M, Polman CH, et al. Double-blind placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS. J Neuroimmunol 1995 ; Suppl 1 : 5.
37. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin-basic-protein autoreactive T-cells by T-cell vaccination: Pilot trial in multiple sclerosis. Lancet 1995 ; 346 : 807-8.
38. Milligan NM, Miller DH, Compston DAS. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1994 ; 57 : 164-8.
39. European Study Group on Interferon beta-1b in Secondary Progressive MS. Lancet 1998 ; 352 : 1491-7.
40. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon β-1a for disease profgression in relapsing remitting multiple sclerosis. Ann Neurol 1996 ; 39 : 285-94.
41. PRISMS. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352 : 1498-504.
42. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988 ; 15 : 266-72.
43. Noseworthy JH, O'Brien P, Erickson BJ. The Mayo Clinic-Canadian cooperative trial of sulfasazine in active multiple sclerosis. Neurology 1998 ; 51 : 1342-52.
44. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology 1998 ; 50 : 1127-33.